4f-mdmb-binaca 4f-mdmb-binaca 4f-mdmb-binaca (also known as 4f-mdmb-butinaca or 4f-adb) is an indazole-based synthetic cannabinoid from the indazole-3-carboxamide family. it has been used as an active ingredient in synthetic cannabis products and sold as a designer drug since late 2018. 4f-mdmb-binaca is an agonist of the cb1 receptor (ec50 = 7.39 nm), though it is unclear whether it is selective for this target. in december 2019, the unodc announced scheduling recommendations placing 4f-mdmb-binaca into schedule ii throughout the world. 4f-mdmb-binacalegal statuslegal status ca: schedule ii de: anlage ii (authorized trade only, not prescriptible) uk: class b un: psychotropic schedule ii identifiers iupac name methyl (s)-2-(1-(4-fluorobutyl)-1h-indazole-3-carboxamido)-3,3-dimethylbutanoate cas number2390036-46-9pubchem cid145707216chemspider71117201uniizh38utm145chemical and physical dataformulac19h26fn3o3molar mass363.433 g·mol−13d model (jsmol)interactive image smiles o=c(n(c(oc)=o)c(c)(c)c)c1=nn(ccccf)c2=c1c=cc=c2 inchi inchi=1s/c19h26fn3o3/c1-19(2,3)16(18(25)26-4)21-17(24)15-13-9-5-6-10-14(13)23(22-15)12-8-7-11-20/h5-6,9-10,16h,7-8,11-12h2,1-4h3,(h,21,24)/t16-/m1/s1key:gzgksdamwrwyoz-mrxnpfedsa-n related compounds the corresponding indole core analogue, 4f-mdmb-bica or 4f-mdmb-butica has also been widely sold as a designer drug by chemical providers on the net, first being identified in may 2020. 4f-mdmb-bica united kingdom it's illegal to sell, distribute, supply, transport or trade the pharmaceutical drug under the psychoactive substances act 2016. in the united states, the dea has filed a notice for its intent to temporarily place 4f-mdmb-butica (but not 4f-mdmb-binaca itself) into schedule i status starting on or after may 4, 2023, for up to 2 years, during which it's possible the dea could file for permanent scheduling within those 2 years. if it is filed on may 4, 2023, and the dea does not file to permanent placement the temporary schedule i order will expire on may 4, 2025.